BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, LLC (“Amneal”), the 7th largest generic drug manufacturer in the U.S., announced today that it has entered into agreements with subsidiaries of Actavis, Inc. (NYSE:ACT) to purchase four generic products for cash consideration. One product is currently marketed in the U.S. by Actavis, two products have Abbreviated New Drug Applications currently awaiting regulatory approval, and one product has been approved but is not currently marketed pursuant to a settlement agreement. The closings of the purchase agreements are contingent upon the consummation of Actavis’ acquisition of Warner Chilcott plc.
Help employers find you! Check out all the jobs and post your resume.
